Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(17):1434-1436; doi:10.1093/jnci/92.17.1434
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Mazumdar, M.
Right arrow Articles by Motzer, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mazumdar, M.
Right arrow Articles by Motzer, R. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 17, 1434-1436, September 6, 2000
© 2000 Oxford University Press

BRIEF COMMUNICATIONS

Calvert's Formula for Dosing Carboplatin: Overview and Concerns of Applicability in High-Dose Setting

Madhu Mazumdar, Alex Smith, William P. Tong, Robert J. Motzer

Affiliations of authors: M. Mazumdar, A. Smith (Department of Epidemiology and Biostatistics), W. P. Tong (Department of Therapeutic Pharmacology), R. J. Motzer (The Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine), Memorial Sloan-Kettering Cancer Center, New York, NY.

Correspondence to: Madhu Mazumdar, Ph.D., Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., Box 44, New York, NY 10021 (e-mail: mazumdar@biost.mskcc.org).

The uniqueness of carboplatin as a chemotherapy drug is in the fact that the systemic drug exposure produced by any dose in a patient can be reasonably estimated on the basis of his or her renal function. Calvert's formula (1) of delivering a calculated dose in terms of target carboplatin area under the time–concentration curve (AUC) and a measured or estimated glomerular filtration rate (GFR) has been widely used.

Here, we describe the derivation of Calvert's formula and point out some limitations in its development, including violation of an underlying assumption of linear regression theory. We also discuss the related published literature and recommend practicing caution in its use for a high-dose setting.

Calvert et al. (1) derived the dosage formula in three stages. Analysis at stage I involved a retrospective look at data from pharmacokinetic studies and . . . [Full Text of this Article]

NOTES

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
G. V. Kondagunta, J. Bacik, J. Sheinfeld, D. Bajorin, M. Bains, L. Reich, J. Deluca, A. Budnick, N. Ishill, M. Mazumdar, et al.
Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin Plus Etoposide in Previously Treated Germ Cell Tumors
J. Clin. Oncol., January 1, 2007; 25(1): 85 - 90.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
J. Goodisman and A.-K. Souid
Constancy in integrated Cisplatin plasma concentrations among pediatric patients.
J. Clin. Pharmacol., April 1, 2006; 46(4): 443 - 448.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Chevreau, F. Thomas, C. Couteau, F. Dalenc, L. Mourey, and E. Chatelut
Ototoxicity of High-Dose Carboplatin
J. Clin. Oncol., May 20, 2005; 23(15): 3649 - 3650.
[Full Text] [PDF]

Home page
 JCOHome page
R. J. Motzer
In Reply:
J. Clin. Oncol., March 15, 2004; 22(6): 1158 - 1159.
[Full Text] [PDF]

Home page
 Ann OncolHome page
M. C. Etienne, F. Leger, X. Pivot, E. Chatelut, R. J. Bensadoun, E. Guardiola, N. Renee, N. Magne, P. Canal, and G. Milano
Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearance
Ann. Onc., April 1, 2003; 14(4): 643 - 647.
[Abstract] [Full Text] [PDF]